Neurogene Inc. (NGNE) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $635.20M; Retained Earnings (Accumulated Deficit)USD $-418.07M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $621.37M; Retained Earnings (Accumulated Deficit)USD $-383.58M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $617.54M; Retained Earnings (Accumulated Deficit)USD $-352.65M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $593.45M; Retained Earnings (Accumulated Deficit)USD $-327.91M.
Neurogene Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $0.00 | $635.20M | $-418.07M | $217.13M | 3 month · $17.00K | 3 month · $7.86M | (m) |
| 2026-03-31 | $0.00 | $0.00 | $621.37M | $-383.58M | $237.78M | (m) | 3 month · $3.63M | (m) |
| 2025-12-31 | $0.00 | $0.00 | $617.54M | $-352.65M | $264.89M | (m) | 12 month · $14.18M | (m) |
| 2025-09-30 | $0.00 | $0.00 | $593.45M | $-327.91M | $265.54M | (m) | 3 month · $3.37M | (m) |
| 2025-06-30 | $0.00 | $0.00 | $580.22M | $-306.96M | $273.25M | (m) | 3 month · $3.41M | (m) |
| 2025-03-31 | $0.00 | $0.00 | $576.74M | $-284.94M | $291.80M | (m) | 3 month · $4.05M | (m) |
| 2024-12-31 | $0.00 | $0.00 | $572.67M | $-262.30M | $310.38M | 12 month · $10.50M | 12 month · $8.32M | (m) |
| 2024-09-30 | $0.00 | $0.00 | $380.20M | $-242.78M | $137.41M | (m) | 3 month · $2.47M | (m) |
| 2024-06-30 | $0.00 | $0.00 | $377.58M | $-222.57M | $155.01M | (m) | 3 month · $2.31M | (m) |
| 2024-03-31 | $0.00 | $0.00 | $374.85M | $-204.07M | $170.78M | (m) | 3 month · $1.04M | (m) |
| 2023-12-31 | $0.00 | $0.00 | $373.18M | $-187.15M | $186.02M | 12 month · $6.95M | 12 month · $1.42M | (m) |
| 2023-09-30 | $0.00 | $0.00 | $547.11M | $-471.87M | $-183.21M | (m) | 3 month · $386.00K | $0.00 |
| 2023-06-30 | $0.00 | $0.00 | $546.93M | $-467.34M | $-169.05M | (m) | 3 month · $384.00K | $-13.00K |
| 2023-03-31 | $0.00 | $0.00 | $546.60M | $-465.26M | $-157.60M | (m) | 3 month · $293.00K | $18.00K |
| 2022-12-31 | $0.00 | $0.00 | $5.10M | $-150.84M | $-145.74M | 12 month · $91.00K | 12 month · $1.25M | $-21.00K |
| 2022-09-30 | $0.00 | $0.00 | $543.35M | $-437.61M | $105.65M | (m) | 3 month · $2.03M | $-92.00K |
| 2022-06-30 | $0.00 | $0.00 | $541.32M | $-424.54M | $116.71M | (m) | 3 month · $2.31M | $-72.00K |
| 2022-03-31 | $0.00 | $0.00 | $538.94M | $-408.85M | $130.09M | (m) | 3 month · $2.45M | (m) |
| 2021-12-31 | $0.00 | $0.00 | $536.36M | $-393.50M | $-91.88M | (m) | 12 month · $11.56M | $0.00 |
| 2021-09-30 | $0.00 | $0.00 | $533.20M | $-378.33M | $154.87M | (m) | 3 month · $3.21M | (m) |
| 2021-06-30 | $0.00 | $0.00 | $529.96M | $-362.88M | $167.07M | (m) | 3 month · $2.92M | (m) |
| 2021-03-31 | $0.00 | $0.00 | $526.72M | $-347.76M | $178.97M | (m) | 3 month · $2.42M | (m) |
| 2020-12-31 | $0.00 | $0.00 | $524.02M | $-332.81M | $191.22M | 12 month · $4.93M | 12 month · $5.62M | (m) |
| 2020-09-30 | (m) | (m) | $520.51M | $-320.17M | $200.34M | (m) | 3 month · $1.69M | (m) |
| 2020-06-30 | (m) | (m) | $446.62M | $-317.92M | $128.70M | (m) | 3 month · $1.02M | (m) |
| 2020-03-31 | (m) | (m) | $445.29M | $-308.17M | $137.12M | (m) | 3 month · $683.00K | (m) |
| 2019-12-31 | $0.00 | $0.00 | $441.22M | $-299.53M | $141.69M | 12 month · $5.53M | 12 month · $7.68M | (m) |
| 2019-09-30 | (m) | (m) | $358.30M | $-291.43M | $66.88M | (m) | 3 month · $5.15M 9 month · $7.02M | (m) |
| 2019-06-30 | (m) | (m) | $304.62M | $-232.30M | $72.33M | (m) | 3 month · $788.00K 6 month · $1.87M | (m) |
| 2019-03-31 | (m) | $0.00 | $303.84M | $-232.29M | $71.54M | (m) | 3 month · $1.08M | (m) |
| 2018-12-31 | (m) | $0.00 | $302.76M | $-230.09M | $72.67M | (m) | 12 month · $4.70M | (m) |
| 2018-09-30 | (m) | $0.00 | $301.92M | $-225.20M | $76.72M | (m) | 3 month · $1.04M 9 month · $3.86M | (m) |
| 2018-06-30 | (m) | $0.00 | $300.89M | $-210.21M | $90.68M | (m) | 3 month · $1.51M 6 month · $2.83M | $-2.00K |
| 2018-03-31 | (m) | $0.00 | $298.97M | $-213.12M | $85.83M | (m) | 3 month · $1.31M | $-24.00K |
| 2017-12-31 | $0.00 | $0.00 | $297.46M | $-198.50M | $98.89M | (m) | 12 month · $3.84M | $-70.00K |
| 2017-09-30 | (m) | $0.00 | $296.43M | $-182.23M | $114.09M | (m) | (m) | $-103.00K |
| 2017-06-30 | (m) | $0.00 | $295.21M | $-170.40M | $124.61M | (m) | (m) | $-205.00K |
| 2017-03-31 | (m) | $0.00 | $293.78M | $-156.63M | $136.94M | (m) | (m) | $-205.00K |
| 2016-12-31 | (m) | $0.00 | $293.11M | $-148.28M | $144.66M | (m) | 12 month · $1.97M | $-169.00K |
| 2016-09-30 | (m) | $0.00 | $292.40M | $-137.03M | $155.36M | (m) | (m) | $-8.00K |
| 2016-06-30 | (m) | $0.00 | $220.91M | $-128.89M | $92.09M | (m) | (m) | $72.00K |
| 2016-03-31 | (m) | $0.00 | $220.42M | $-117.99M | $102.39M | (m) | (m) | $-47.00K |
| 2015-12-31 | (m) | $0.00 | $219.99M | $-111.28M | $108.42M | (m) | 12 month · $1.51M | $-290.00K |
| 2015-09-30 | (m) | $0.00 | $219.64M | $-105.61M | $114.03M | (m) | (m) | $3.00K |
| 2015-06-30 | (m) | $0.00 | $126.38M | $-100.58M | $25.81M | (m) | (m) | $4.00K |
| 2015-03-31 | (m) | $0.00 | $125.90M | $-95.83M | $30.08M | (m) | (m) | $3.00K |
| 2014-12-31 | (m) | $0.00 | $125.57M | $-89.42M | $36.15M | (m) | 10 month · $754.77K 12 month · $855.00K | $-4.00K |
| 2014-09-30 | (m) | (m) | $125.30M | $-81.33M | $43.98M | (m) | (m) | $7.30K |
| 2014-06-30 | (m) | (m) | $125.06M | $-75.04M | $50.02M | (m) | (m) | $880.00 |
| 2014-03-31 | (m) | (m) | $124.71M | (m) | $55.10M | (m) | (m) | (m) |
| 2014-03-12 | (m) | (m) | (m) | (m) | $-65.39M | (m) | 2 month · $99.42K | (m) |
| 2013-12-31 | (m) | (m) | (m) | $-65.69M | $-65.69M | (m) | 12 month · $349.00K | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | $-51.10M | (m) | 12 month · $351.32K | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | $-39.31M | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | $-25.11M | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | $-14.11M | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | $-8.93M | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | (m) | (m) | $-2.43M | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | (m) | (m) | $10.71K | (m) | (m) | (m) |
| 2005-12-31 | (m) | (m) | (m) | (m) | $-31.01K | (m) | (m) | (m) |
| 2004-12-31 | (m) | (m) | (m) | (m) | $-11.39K | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |